Sep 24, 2026
Dr. Seth Lederman, CEO and Co-Founder of Tonix, describes the company's focus on chronic, debilitating, and underserved medical conditions that have been overlooked. Fibromyalgia, a common chronic pain condition, is a prime focus, and Seth explains how recognition of this neurological condition rooted in the central...
Sep 24, 2026
Dr. Seth Lederman, CEO and Co-Founder of Tonix, describes the company's focus on chronic, debilitating, and underserved medical conditions that have been overlooked. Fibromyalgia, a common chronic pain condition, is a prime focus, and Seth explains how recognition of this neurological condition rooted in the central...
Sep 16, 2026
Andrew Hall, CEO of Consano Bio, is developing an allogeneic approach to treat chronic sciatica by activating healing in damaged spinal nerves, emulating the natural healing properties of human platelets. This condition currently has no approved treatments and is managed through symptomatic approaches like opioids,...
Sep 16, 2026
Andrew Hall, CEO of Consano Bio, is developing an allogeneic approach to treat chronic sciatica by activating healing in damaged spinal nerves, emulating the natural healing properties of human platelets. This condition currently has no approved treatments and is managed through symptomatic approaches like opioids,...
Feb 10, 2026
Brent Ness, CEO and President of Aclarion, highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful...